Faron Pharmaceuticals Oy
(OHEL:FARON)
€
1.91
-0.01 (-0.52%)
Market Cap: 191.86 Mil
Enterprise Value: 174.61 Mil
PE Ratio: 0
PB Ratio: 139.64
GF Score: 36/100 Faron Pharmaceuticals Oy at Canaccord Genuity Growth Conference Transcript
Aug 10, 2023 / 04:30PM GMT
Release Date Price:
€2.86
(-1.98%)
John Newman
Canaccord Genuity Group Inc. - Analyst
Good afternoon, everyone, and thank you for joining us at the 43rd Annual Canaccord Genuity Growth Conference. I'm John Newman, one of the biotech analysts here at Canaccord based in New York.
We're very excited to have Faron with us today. And joining us are the CEO, Markku Jalkanen; and the CMO, Marie-Louise Fjällskog. So welcome to you both.
Marie;Louise FjÃ;llskog
Faron Pharmaceuticals Oy - Chief Medical Officer
¤ -
Thank you.
Questions & Answers
John Newman
Canaccord Genuity Group Inc. - Analyst
I'm going to take a seat over here now. So thanks for joining us. I'm wondering if we could start by talking about your lead assets, excuse me, bexmarilimab. I believe this targets something called Clever-1. Could you first talk to us about the importance of this target, biologically?
Markku Jalkanen
Faron Pharmaceuticals Oy - CEO & Executive Director
Absolutely.
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot